We are live on ! Find out more
TRIB

Trinity Biotech

79 hedge funds and large institutions have $191M invested in Trinity Biotech in 2016 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 30 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

0% more funds holding

Funds holding: 7979 (0)

6% less capital invested

Capital invested by funds: $203M → $191M (-$11.3M)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

43% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 30

94% less call options, than puts

Call options by funds: $1K | Put options by funds: $18K

Holders
79
Holders Change
Holders Change %
0%
% of All Funds
2.11%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
7
Increased
17
Reduced
30
Closed
6
Calls
$1K
Puts
$18K
Net Calls
-$17K
Net Calls Change
+$99K

TRIB Hedge Fund Activity: Q2 2016 in Review

79 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q2 2016, worth a combined $191M — down 5.6% from $203M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new TRIB positions and 6 closed out — a net gain of 1 holder — while 17 added to existing stakes and 30 trimmed.

The largest buyer was Paradice Investment Management, adding an estimated $2.15M. The largest seller was Bank of Montreal, cutting an estimated $3.24M.

  • 79 institutional investors held Trinity Biotech (TRIB) as of Q2 2016, unchanged from Q1 2016.
  • Funds reported $191M of Trinity Biotech stock for Q2 2016, down 5.6% quarter-over-quarter.
  • 7 funds opened new Trinity Biotech positions in Q2 2016 and 6 closed out, a net change of +1 holder.
  • The largest Trinity Biotech buyer in Q2 2016 was Paradice Investment Management, an estimated $2.15M added.
  • The largest Trinity Biotech seller in Q2 2016 was Bank of Montreal, an estimated $3.24M sold.

Based on aggregated 13F filings for Q2 2016.